Effect of cyp1a1, cyp1b1 and cyp2c gene polymorphisms on doxorubicin and paclitaxel

The genes encoding metabolizing cytochrome P450 enzyme are studied for their importance in cancer susceptibility. Therefore, it is of interest to identify the correlation of CYP1A, CYP1B and CYP2C gene polymorphisms on drug response (DG-RS) and toxicity reactions in Indian population. Hence, 200 breast cancer patients received doxorubicin (DXR) and paclitaxel (PCX) chemotherapy. Further, chemotherapy induced hematological (HEM) and none (N)-HEM toxicity reactions were recorded. We found that, the Univariate Logistic Regression analysis showed negative association of CYP1B1 (4326 C>G) gene polymorphisms with microsites (OR=0.14, 95% CI: 0.03-0.54; p=0.004) in breast cancer patients treated with Doxorubicin. Thus, protective effect of CYP1B1-polymorphisms with doxorubicin and paclitaxel based chemotherapy induced N-HEM toxicity and CYP2C9- polymorphisms with paclitaxel induced body ache and CYP1A1-polymorphisms with peripheral neuropathy in breast cancer patients.